
A team of great scientists from different nations who turn cancer defects into novel treatments

Welcome to the Helleday Laboratory

Targeting DNA Glycosylase OGG1 in inflammation
Interested in a different publication?
We aim to improve science, health and society! Our commitment does not stop with science at the basics; we bring our results all the way to the patients.
The Helleday Laboratory consists of a large team of mixed professions from industry and academia; basic molecular biologists, medicinal chemists, pharmacologists, biochemists and practicing clinicians, amongst others. What brings us together is our dedication to make our basic science discoveries reach all the way to helping patients stay healthy and with their loved ones.
The Helleday Laboratory mostly focuses on metabolism and DNA repair, and recently inflammation.
The Nobel Prize laureate Otto Warburg who pioneered modern cancer metabolism research once said that “The cure of human cancer will be the resultant of biochemistry of cancer and of biochemistry of man“. We could not agree more. With today’s molecular knowledge of altered metabolic pathways in cancer cells we are making real advances in progressing cancer treatments. Read about how we target glucose metabolism and nucleotide metabolism. Chemo- and radiotherapy is still the backbone of cancer treatments, and they work by causing damage to the cancer cells DNA. We know today that cancer cells have a high load of DNA damage as compared to normal cells. Read about DNA damage and repair in cancer. Previously, the Helleday lab has exploited this and shown that PARP inhibitors selectively kill recombination defective cancers, such as inherited breast- and ovarian cancer. This is now an approved treatment and help patients across the world.
News
Prisregn över Helledaylaboratoriets Sean Rudd
Vår postdoc Sean Rudd har hittills haft en riktigt bra vecka. I onsdags belönades han med priset ”SciLifeLab Highlight of the year 2016″ på SciLifeLab summit här i Solna, och igår kom beskedet att Sean har fått 200 000kr från Alex och Eva Wallströms stiftelse för hans...
Välkommen Åsa!
När det stora ebolautbrottet skedde för ett par år sedan testade vi våra proteinhämmare för att se om de kunde användas till att döda av ebolavirus. Till vår förvåning hittade vi en substansfamilj som inte bara effektivt dödade av ebolaviruset utan också en rad andra...
Our new clinical trial with MTH1 inhibitors now have a name – MASTIFF
We have now set a name for our phase I clinical trial, MASTIFF, which stands for "Mth1, A phase I, Study on Tumor Inhibition, First in human, First in class clinical trial". The study is a dose escalation study with the aim to identify a safe dose for phase II...